0
ARTICLE |

THE TREATMENT OF PNEUMOCOCCIC PNEUMONIA WITH SULFADIAZINE

HARRY F. DOWLING, M.D.; CLARENCE R. HARTMAN, M.D.; SAMUEL J. SUGAR, M.D.; HARRY A. FELDMAN, M.D.
JAMA. 1941;117(10):824-826. doi:10.1001/jama.1941.02820360006003.
Text Size: A A A
Published online

Extensive clinical use has established beyond doubt the value of sulfapyridine and sulfathiazole in the treatment of pneumococcic pneumonia. Among the many similar compounds that have been synthesized, one in particular has shown sufficient promise in preliminary studies to be worthy of clinical trial. This compound, sulfadiazine (2-sulfanilamidopyrimidine) is the pyrimidine analogue of sulfapyridine, synthesized by Roblin and his associates.1 Feinstone and his co-workers2 administered sulfadiazine to various laboratory animals and obtained higher average blood levels than after the administration of similar dosages of sulfapyridine or sulfathiazole. The therapeutic effects with sulfadiazine were equal or superior to those with sulfapyridine or sulfathiazole, and the toxic reactions were less frequent. Studies on the absorption and excretion of sulfadiazine in human beings have been made by several groups of investigators3 who agreed that higher levels of the drug in the blood were obtained and that these persisted over a

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();